MA45169A - Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire - Google Patents

Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire

Info

Publication number
MA45169A
MA45169A MA045169A MA45169A MA45169A MA 45169 A MA45169 A MA 45169A MA 045169 A MA045169 A MA 045169A MA 45169 A MA45169 A MA 45169A MA 45169 A MA45169 A MA 45169A
Authority
MA
Morocco
Prior art keywords
endometric
treatment
ovarian cancer
vaccine therapy
vaccine
Prior art date
Application number
MA045169A
Other languages
English (en)
Inventor
George E Peoples
Original Assignee
Sellas Life Sciences Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sellas Life Sciences Group Inc filed Critical Sellas Life Sciences Group Inc
Publication of MA45169A publication Critical patent/MA45169A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045169A 2016-05-31 2017-05-31 Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire MA45169A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662343675P 2016-05-31 2016-05-31

Publications (1)

Publication Number Publication Date
MA45169A true MA45169A (fr) 2019-04-10

Family

ID=59239944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045169A MA45169A (fr) 2016-05-31 2017-05-31 Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire

Country Status (4)

Country Link
US (1) US11338025B2 (fr)
EP (1) EP3463438B1 (fr)
MA (1) MA45169A (fr)
WO (1) WO2017210255A1 (fr)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
CA2150100C (fr) 1994-10-31 2006-11-28 James Kuchar Branchement electrique pour projecteur sur rail
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
WO1997025068A2 (fr) 1996-01-05 1997-07-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antigene de mesothelium, procedes et kits de ciblage de celui-ci
CN1571834B (zh) 2001-02-20 2013-03-20 奥索-麦克尼尔药品公司 用于***的细胞疗法
JP4401075B2 (ja) 2001-03-09 2010-01-20 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 葉酸結合タンパク質の改変体による腫瘍免疫の誘導
ATE427948T1 (de) 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2685300C (fr) 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunite vis-a-vis des recepteurs de folate
JP5635399B2 (ja) * 2007-06-01 2014-12-03 ザ ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド 乳癌再発の予防のためのワクチン
WO2016196506A1 (fr) * 2015-05-29 2016-12-08 Galena Biopharma, Inc. Vaccinothérapie peptidique pour le traitement de tumeurs exprimant frα

Also Published As

Publication number Publication date
US11338025B2 (en) 2022-05-24
EP3463438A1 (fr) 2019-04-10
EP3463438B1 (fr) 2022-04-06
US20180256692A1 (en) 2018-09-13
WO2017210255A1 (fr) 2017-12-07

Similar Documents

Publication Publication Date Title
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
MA45563A (fr) Méthodes de traitement du cancer de l'ovaire
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA48637A (fr) Polythérapies pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA41449A (fr) Polythérapies pour le traitement de cancers
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA47719A (fr) Esketamine pour le traitement de la dépression
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
MA52252A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
MA44413A (fr) Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA45406A (fr) Inhibiteurs d'ezh2 pour traiter le cancer